Fotemustine Compared With Dacarbazine in Patients ...

Phase 3 study of docosahexaenoic acid–paclitaxel versus ...

No significant difference in OS was noted between patients in the DHA–paclitaxel and dacarbazine arms. Similarly, there were no significant differences in ...

(PDF) Phase III randomized study of fotemustine and dacarbazine ...

PDF | The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced ...

A randomized phase III study comparing dacarbazine, BCNU ...

This article is cited by · Temozolomide in combination with fotemustine in patients with metastatic melanoma · Combination chemotherapy with or ...

PCN1 QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS ... - ISPOR

PCN1 QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) OF FOTEMUSTINE COMPARED WITH DACARBAZINE IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA.

A phase III study | Documentos - Universidad Complutense de Madrid

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. Avril, M.F.; Aamdal, S. Grob, J.J.; Hauschild, A.

DCRB - Cancer Care Ontario

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. JCO 2004; 22:1118-25. Therapy for metastatic ...

Fotemustine plus dacarbazine for malignant melanoma - European ...

The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences ...

Economic evaluation of ipilimumab in first line treatment of ...

Fotemustine compared with ... Randomized phase. III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic ...

Bevacizumab plus Fotemustine as First-line Treatment in Metastatic ...

In a randomized trial (13) comparing fotemustine with dacarbazine, as first-line chemotherapy in 229 patients, with or without brain metastases, overall ...

Fotemustine, dacarbazine, vindesine combination chemotherapy in ...

Fotemustine and dacarbazine constitute the most active single chemotherapeutic agents in the treatment of melanoma. In this phase II study we evaluated the ...

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?

DHA-paclitaxel has been compared in one phase III trial against dacarbazine in melanoma patients in the 1L setting — with comparable ORRs (5.2 ...

Latest Advances in Chemotherapeutic, Targeted, and Immune ...

Fotemustine compared with dacarbazine in patients with disseminated malignant mela- noma: a phase III study. J Clin Oncol. 2004;22(6):1118-1125. 26. Glover D, ...

CHEBI:131848 - fotemustine - EMBL-EBI

A study has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of ...

[PDF] Improved survival with vemurafenib in melanoma with BRAF ...

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. M. AvrilS. Aamdal +17 authors. Y. Menu. Medicine.

Systemic therapies for melanoma brain metastases: which drug for ...

Phase 3 trials of dabrafenib and vemurafenib showed significantly improved response rates, progression free and OS, in comparison to dacarbazine, in BRAF ...

Combined vemurafenib and fotemustine in patients with BRAF V600 ...

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study. J Clin Oncol. 2004; 22: 1118–1125 ...

The History and Future of Chemotherapy for Melanoma

27. Avril, M.F. ∙ Aamdal, S. ∙ Grob, J.J. ... Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J ...

Treatment of Metastatic Melanoma: An Overview - Cancer Network

[23] When compared to dacarbazine in a phase III trial involving 229 patients ... fotemustine arm vs 7.2 months in the dacarbazine arm.

Gaining momentum - Rutgers Cancer Institute

Historically, systemic treatment of patients with advanced mel- anoma centred on cytostatic chemotherapy with dacarbazine or other alkylating agents such as ...

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 ...

Most importantly, the 4-year OS rate was significantly higher in patients receiving ipilimumab plus nivolumab as compared with fotemustine (41% ...